Moraxella catarrhalis

Last updated

Moraxella catarrhalis
Moraxella Catarrhalis.png
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Bacteria
Phylum: Pseudomonadota
Class: Gammaproteobacteria
Order: Pseudomonadales
Family: Moraxellaceae
Genus: Moraxella
Species:
M. catarrhalis
Binomial name
Moraxella catarrhalis
(Frosch and Kolle 1896) Henriksen and Bøvre 1968 [1]

Moraxella catarrhalis is a fastidious, nonmotile, Gram-negative, aerobic, oxidase-positive diplococcus that can cause infections of the respiratory system, middle ear, eye, central nervous system, and joints of humans. It causes the infection of the host cell by sticking to the host cell using trimeric autotransporter adhesins.

Contents

Epidemiology

Moraxella catarrhalis is a human pathogen with an affinity for the human upper respiratory tract and the middle ear. Other primates, such as macaques, might become infected by this bacterium. [2] Rodents including rats, mice, and chinchillas have been used to study Moraxella catarrhalis with varying degrees of success. [3]

History

The taxonomy of Moraxella catarrhalis is a topic that has caused confusion in the past. The bacteria was initially placed in the genus Neisseria , before being moved into a separate genus named Branhamella in honor of Dr. Sara Branham in 1970. [4] In 1984 this bacterium once again had a change in taxonomy and was moved to the genus Moraxella . Some individuals disagreed with this change, the rationale being that other members of the genus Moraxella are rod-shaped and rarely caused infections in humans. [4] However, results from DNA hybridization studies and 16S rRNA sequence comparisons were used to justify inclusion of the species M. catarrhalis in the genus Moraxella. [5] As a consequence, the name Moraxella catarrhalis is currently preferred for these bacteria. Nevertheless, some in the medical field continue to call these bacteria Branhamella catarrhalis. [4]

Moraxella is named after Victor Morax, a Swiss ophthalmologist who first described this genus of bacteria. Catarrhalis is derived from catarrh, from the Greek meaning "to flow down" (cata- implies down; -rrh implies flow), describing the profuse discharge from eyes and nose typically associated with severe inflammation in colds. [6]

Genetics

The whole genome sequence of M. catarrhalis CCUG 353 type strain was deposited and published in DNA Data Bank of Japan, European Nucleotide Archive, and GenBank in 2016 under the accession number LWAH00000000. [7] The genome was sequenced using a hybrid assembly from two different instrumental methods, Illumina MiSeq and Ion Torrent, and the final assembly produced was composed of 18 contigs. [7] The genome was found to be 1,886,586 bp in length, encoding for 1,736 total genes. [8]

Clinical significance

This bacterium has been known to cause otitis media, [9] [10] bronchitis, sinusitis, and laryngitis. Elderly patients and long-term heavy smokers with chronic obstructive pulmonary disease should be aware that M. catarrhalis is associated with bronchopneumonia, as well as exacerbations of existing chronic obstructive pulmonary disease. Current estimates have M. catarrhalis as the cause of approximately 10% of all chronic obstructive pulmonary disease exacerbations, impacting millions of people each year. [11]

The peak rate of colonization by M. catarrhalis appears to occur around 2 years of age, with a striking difference in colonization rates between children and adults (very high to very low).

Moraxella catarrhalis has recently been gaining attention as an emerging human pathogen. It has been identified as an important cause in bronchopulmonary infection, causing infection through pulmonary aspiration in the upper pulmonary tract. [12] Additionally, it causes bacterial pneumonia, especially in adults with a compromised immune system. [13] It has also been known as an important cause in acute sinusitis, maxillary sinusitis, bacteremia, meningitis, conjunctivitis, acute purulent irritation of chronic bronchitis, urethritis, sepsis (although this is rare), septic arthritis (which is also a rare occurrence), and acute laryngitis in adults and acute otitis media in children. [14] [15] M. catarrhalis is an opportunistic pulmonary invader, and causes harm especially in patients who have compromised immune systems or any underlying chronic disease. [12] [14]

Moraxella catarrhalis has also been linked with septic arthritis in conjunction with bacteremia. [14] Although cases of bacteremia caused by M. catarrhalis have been reported before, this was the first instance in which bacteremia caused by M. catarrhalis was also associated with septic arthritis. A microbiological evaluation of the patient (a 41-year-old male) revealed that M. catarrhalis was the cause of the disease rather than Neisseria as was previously believed. This was also the second case of M. catarrhalis causing septic arthritis (although in the first case, no mention of bacteremia was made). [14]

Along with its relation to septic arthritis, bacteremia is also caused by M. catarrhalis infection, which can range in severity from a slight fever to lethal sepsis and an associated respiratory tract infection is usually also identified. [16] Bacteremia infections caused by M. catarrhalis have a 21% mortality rate among patients. However, this may have been due to a lack of knowledge about the bacterium because of its recent recognition as a pathogen. [16]

Infection of high-grade bacteremia was linked with the development of endocarditis. [16] However, the patients without endocarditis has been related to the background of each patient, especially the existence of other illnesses and any possible immune impairments they may have. Also, although bacteremia caused by M. catarrhalis has been infrequently reported, M. catarrhalis was only recently (1990s) identified as an important pathogen. [16] Cases of M. catarrhalis infection have been misdiagnosed as normal lung flora or disregarded due to a lack of importance in the pathogen screening at the time, contributing to the trend of infrequent reporting of M. catarrhalis. [16] Many chronic diseases in patients with M. catarrhalis bacteremia can be linked to the patients with immune defects or respiratory debility. Likewise, respiratory debility in patients with bacteremic pneumonia caused by M. catarrhalis infection can be linked with increased rates of pharyngeal colonization, enhancement of bacterial adherence to abnormal epithelium, and increased susceptibility of pulmonary parenchyma to infection. [16]

Antibiotic resistance

Antibiotic sensitivity test: This strain shows resistance to ampicillin because it produces the enzyme b-lactamase. This is confirmed by the disc (nitrocefin) labelled b turning red. M. cat BSAC.JPG
Antibiotic sensitivity test: This strain shows resistance to ampicillin because it produces the enzyme β-lactamase. This is confirmed by the disc (nitrocefin) labelled β turning red.

Moraxella catarrhalis can be treated with antibiotics, but it is commonly resistant to penicillin, ampicillin, and amoxicillin. [16]

Current research priorities involve trying to find a suitable vaccine [17] for this genotypically diverse organism, as well as determining factors involved with virulence, e.g. complement resistance. Lipooligosaccharide is considered one possible virulence factor. [17]

Since the recent recognition of M. catarrhalis as an important pathogenic microbe, development of a possible antibiotic has been ongoing. A fraction of M. catarrhalis strains seemed to be resistant to ampicillin, which makes ampicillin and amoxicillin inappropriate choices of antibiotic against it. [12] Although all strains of M. catarrhalis were susceptible to cotrimoxazole, erythromycin, sulfadimidine, and tetracycline, they were also resistant to trimethoprim. [12] M. catarrhalis resistance to beta-lactam antibiotics, such as ampicillin, is mediated by periplasmic lipoprotein beta-lactamases BRO-1 and BRO-2, which protect the peptidoglycan layer by hydrolyzing the beta-lactam molecules that enter the bacterial cell. [18] Research found that of the isolated strains of M. catarrhalis that were beta-lactamase positive, approximately 6% had BRO-2 beta-lactamase, while the remaining 94% had BRO-1 beta-lactamase. [19] The beta-lactamases are produced in the cytoplasm and translocated to the periplasmic space by twin-arginine translocation pathway, which is a protein secretion pathway that transports proteins across a bilipid membrane in a folded state. [20] M. catarrhalis produces and secretes beta-lactamase containing outer-membrane vesicles that can function as an extracellular delivery system of beta-lactam resistance that promotes the survival of otherwise beta-lactam sensitive bacteria in the vicinity of M. catarrhalis. This behavior is beneficial for the other bacteria and can make the antibiotic treatment of polymicrobial infections more difficult. [21] Also, the resistance of M. catarrhalis to other antibiotics may be attributed to beta-lactamase, as well, because the use of these antibiotics has triggered an increase in development of beta-lactamase, which resists antibiotics. [12]

However, a 1994 study has identified a large protein on the surface of M. catarrhalis that may serve as a target for protective antibodies. [13] This UspA (the designated antigen) protein is the first surface-exposed protein on M. catarrhalis that can be a target for biologically active antibodies, and therefore lead to a vaccination. This protein was also present in all of the strains tested. The large size of the exposed protein macromolecule makes it similar to Neisseria gonorrhoeae outer membrane protein macromolecular complex, which implies that UspA may be a single polypeptide chain. [13]

Active immunization, in a study, of M. catarrhalis in the respiratory tract allowed the control of the growth of M. catarrhalis and led to the development of serum antigens. [15] Also, an enhanced ability exists in the test subjects (mice) to clear M. catarrhalis from their lungs. Likewise, passive immunization of M. catarrhalis from the mice respiratory tracts also enhanced the mice's ability to clear the microbes from their lungs, which means that serum antibodies likely play a large role in the immunization and protection of the respiratory tract. [15] Along with outer membrane proteins that are consistent among different strains of M. catarrhalis, a sort of subclass-specific IgG antibody response to certain outer membrane proteins may also exist. Therefore, the outer membrane antigens of M. catarrhalis also provide a possible vaccine source. Also, a bactericidal serum antibody has also been developed in response to the diseases caused by M. catarrhalis. [15]

Treatment

Treatment options include antibiotic therapy or a so-called "watchful waiting" approach. The great majority of clinical isolates of this organism produce beta-lactamases, so are resistant to penicillin. M. catarrhalis can be treated oral antibiotics including trimethoprim-sulfamethoxazole (TMP-SMX), tetracycline, fluoroquinolones, most second- and third-generation cephalosporins, erythromycin, and amoxicillin-clavulanate. [11] Additionally, because there is co-occurrence of M. catarrhalis with Streptococcus pneumonia and Haemophilus influenzae in clinical cases, treatments usually include agents that are also effective against S. pneumonia and H. influenzae. [11]

Vaccine development

Currently, no vaccine is known in the US against M. catarrhalis infection. It is a significant cause of otitis media and respiratory tract infections against which a vaccine is sought. Support for developing a vaccine against M. catarrhalis is the potential of preventative care. [22] A vaccine against M. catarrhalis has been sought after to develop protective immunity in individuals that are at higher risk of infection from this bacterium, such as COPD patients. [22] Vaccine candidates for M. catarrhalis are dependent on multiple factors, including whether the candidates are expressed on the surface of the cell, whether they are conserved across different strains of M. catarrhalis, whether they play a role in the colonization of the bacteria, or whether they cause an immune response in individuals infected. [22]

Several outer membrane proteins have been investigated for their potential role in generating a vaccine against M. catarrhalis. These include adhesin proteins UspA2, Mcap, MhaB1, MhaB2, and dLOS; UspA2 in particular has gone through and completed Phase 1 and 2 clinical trials. [23] MhaB1, MhaB2, and dLOS meanwhile have been investigated in animal studies using immunized mice and chinchillas. [23] Another class of antigens that have been targeted include porin proteins such as M35, OMP E, and OMP CD, which have all been found to be highly conserved across M. catarrhalis strains. Porin M35 was sequenced and found to have almost 100% conservation among isolated samples of M. catarrhalis, and produced immune responses and bacteria clearance in mice. [23] Substrate-binding proteins and Moraxella surface proteins have also been looked for their potential in developing a vaccine, and testing has confirmed some of these proteins are present in many strains of M. catarrhalis and produce immune responses in animal models. [23]

Biochemistry

Figure showing the hockey puck test, where M. catarrhalis bacterial colonies are pushed around on an agar plate by a stick to observe if they retain their shape. This is an test to differentiate M. catarrhalis from other bacterial strains. Hockey Puck Test Graphic.png
Figure showing the hockey puck test, where M. catarrhalis bacterial colonies are pushed around on an agar plate by a stick to observe if they retain their shape. This is an test to differentiate M. catarrhalis from other bacterial strains.

During the first reported case of M. catarrhalis causing bacteremia that was associated with septic arthritis, the microbe was cultured, which revealed much about the morphology of its colonies, as well as M. catarrhalis itself. [14] M. catarrhalis is a large, kidney-shaped, Gram-negative diplococcus. It can be cultured on blood and chocolate agar plates after an aerobic incubation at 37 °C for 24 hours. Cultures revealed gray-white hemispheric colonies about 1 mm in diameter. These colonies were fragile and easy to crumble, and appeared to have a waxy surface. [14]

The hockey puck test was applied to these M. catarrhalis colonies, [14] in which a wooden stick is used to try to push the colonies across the plate. The M. catarrhalis colonies scored positively on this test, which means they could be slid across the plate. The colonies did not demonstrate hemolysis, and were not able to ferment glucose, sucrose, maltose, or lactose. They were able to produce DNase. Cultures of the M. catarrhalis tested positive for oxidase, lipase, and nitrate reduction, which is characteristic of M. catarrhalis. [14] Many laboratories also perform a butyrate esterase test and a beta-lactamase test. Both tests should be positive and can help to rapidly identify it from a culture. [25]

The recognition of M. catarrhalis as a pathogen has led to studies for possible antibodies against it, which have led to a wider understanding of its composition. The outer membrane protein (OMP) profiles of different strains of M. catarrhalis are extremely similar to each other. [13] Analyses of these OMP profiles with monoclonal antibodies (MAbs) revealed that a few proteins with similar molecular masses in the different strains have cross-reactive epitopes. [13] Also, a surface-exposed protein on M. catarrhalis has an unusually high molecular mass. An 80-kDa OMP on M. catarrhalis is immunogenic and common to all nonencapsulated strands of M. catarrhalis, which suggests it may be used as an antigen for immunization. [13]

Protein secretion

Moraxella catarrhalis utilizes the twin-arginine translocation pathway (TAT pathway) for the transport of folded proteins across the inner membrane. [20] The translocase apparatus is a typical Gram-negative TAT translocase consisting of three essential membrane proteins: TatA, TatB and TatC. TatA proteins form a pore through which passenger proteins are transported and TatB and TatC proteins recognize, bind and direct the passenger proteins to the membrane spanning TatA pore. [20] [26]

The M. catarrhalis TAT translocase protein encoding genes tatA, tatB and tatC are located in a single tatABC locus in the bacterial chromosome and are likely to be transcriptionally and translationally linked due to a single-nucleotide overlap between each gene. [20]

Multiple M. catarrhalis proteins have been predicted or tested to contain the highly conserved leader motif for translocation and to be transported by the TAT pathway. Beta-lactamases BRO-1 and BRO-2 have been shown to be transported by the TAT pathway. Other potential passenger proteins include an iron-dependent peroxidase -like protein, a cytochrome c -like protein and a phosphate ABC transporter inner membrane protein- like protein. A functioning TAT pathway is necessary for the optimal growth of M. catarrhalis even in conditions without antibiotics. [20]

Related Research Articles

<span class="mw-page-title-main">Gram-negative bacteria</span> Group of bacteria that do not retain the Gram stain used in bacterial differentiation

Gram-negative bacteria are bacteria that, unlike gram-positive bacteria, do not retain the crystal violet stain used in the Gram staining method of bacterial differentiation. Their defining characteristic is their cell envelope, which consists of a thin peptidoglycan cell wall sandwiched between an inner (cytoplasmic) membrane and an outer membrane. These bacteria are found in all environments that support life on Earth.

<i>Streptococcus</i> Genus of bacteria

Streptococcus is a genus of gram-positive or spherical bacteria that belongs to the family Streptococcaceae, within the order Lactobacillales, in the phylum Bacillota. Cell division in streptococci occurs along a single axis, thus when growing they tend to form pairs or chains, which may appear bent or twisted. This differs from staphylococci, which divide along multiple axes, thereby generating irregular, grape-like clusters of cells. Most streptococci are oxidase-negative and catalase-negative, and many are facultative anaerobes.

<i>Streptococcus pyogenes</i> Species of bacterium

Streptococcus pyogenes is a species of Gram-positive, aerotolerant bacteria in the genus Streptococcus. These bacteria are extracellular, and made up of non-motile and non-sporing cocci that tend to link in chains. They are clinically important for humans, as they are an infrequent, but usually pathogenic, part of the skin microbiota that can cause group A streptococcal infection. S. pyogenes is the predominant species harboring the Lancefield group A antigen, and is often called group A Streptococcus (GAS). However, both Streptococcus dysgalactiae and the Streptococcus anginosus group can possess group A antigen as well. Group A streptococci, when grown on blood agar, typically produce small (2–3 mm) zones of beta-hemolysis, a complete destruction of red blood cells. The name group A (beta-hemolytic) Streptococcus is thus also used.

<i>Staphylococcus aureus</i> Species of gram-positive bacterium

Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe, meaning that it can grow without oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA). The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.

Bloodstream infections (BSIs) are infections of blood caused by blood-borne pathogens. The detection of microbes in the blood is always abnormal. A bloodstream infection is different from sepsis, which is characterized by severe inflammatory or immune responses of the host organism to pathogens.

<span class="mw-page-title-main">Lipopolysaccharide</span> Class of molecules found in the outer membrane of gram-negative bacteria

Lipopolysaccharide, now more commonly known as endotoxin, is a collective term for components of the outermost membrane of cell envelope of gram-negative bacteria, such as E. coli and Salmonella with a common structural architecture. Lipopolysaccharides (LPS) are large molecules consisting of three parts: an outer core polysaccharide termed the O-antigen, an inner core oligosaccharide and Lipid A, all covalently linked. In current terminology, the term endotoxin is often used synonymously with LPS, although there are a few endotoxins that are not related to LPS, such as the so-called delta endotoxin proteins produced by Bacillus thuringiensis.

<span class="mw-page-title-main">Respiratory syncytial virus</span> Species of virus

Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse.

<i>Streptococcus pneumoniae</i> Species of bacterium

Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, spherical bacteria, alpha-hemolytic member of the genus Streptococcus. S. pneumoniae cells are usually found in pairs (diplococci) and do not form spores and are non motile. As a significant human pathogenic bacterium S. pneumoniae was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.

<i>Klebsiella pneumoniae</i> Species of bacterium

Klebsiella pneumoniae is a Gram-negative, non-motile, encapsulated, lactose-fermenting, facultative anaerobic, rod-shaped bacterium. It appears as a mucoid lactose fermenter on MacConkey agar.

<i>Haemophilus influenzae</i> Species of bacterium

Haemophilus influenzae is a Gram-negative, non-motile, coccobacillary, facultatively anaerobic, capnophilic pathogenic bacterium of the family Pasteurellaceae. The bacteria are mesophilic and grow best at temperatures between 35 and 37 °C.

<span class="mw-page-title-main">Bacterial pneumonia</span> Disease of the lungs

Bacterial pneumonia is a type of pneumonia caused by bacterial infection.

<i>Neisseria meningitidis</i> Species of bacterium that can cause meningitis

Neisseria meningitidis, often referred to as the meningococcus, is a Gram-negative bacterium that can cause meningitis and other forms of meningococcal disease such as meningococcemia, a life-threatening sepsis. The bacterium is referred to as a coccus because it is round, and more specifically a diplococcus because of its tendency to form pairs.

Moraxella is a genus of gram-negative bacteria in the family Moraxellaceae. It is named after the Swiss ophthalmologist Victor Morax. The organisms are short rods, coccobacilli, or as in the case of Moraxella catarrhalis, diplococci in morphology, with asaccharolytic, oxidase-positive, and catalase-positive properties. M. catarrhalis is the clinically most important species under this genus.

Capnocytophaga is a genus of Gram-negative bacteria. Normally found in the oropharyngeal tract of mammals and are involved in the pathogenesis of some animal bite wounds and periodontal diseases.

<span class="mw-page-title-main">Cefditoren</span> Chemical to treat skin infections

Cefditoren, also known as cefditoren pivoxil is an antibiotic used to treat infections caused by Gram-positive and Gram-negative bacteria that are resistant to other antibiotics. It is mainly used for treatment of community acquired pneumonia. It is taken by mouth and is in the cephalosporin family of antibiotics, which is part of the broader beta-lactam group of antibiotics.

β-Lactamase inhibitor Drugs that inhibit β-Lactamase enzymes

Beta-lactamases are a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. In bacterial resistance to beta-lactam antibiotics, the bacteria have beta-lactamase which degrade the beta-lactam rings, rendering the antibiotic ineffective. However, with beta-lactamase inhibitors, these enzymes on the bacteria are inhibited, thus allowing the antibiotic to take effect. Strategies for combating this form of resistance have included the development of new beta-lactam antibiotics that are more resistant to cleavage and the development of the class of enzyme inhibitors called beta-lactamase inhibitors. Although β-lactamase inhibitors have little antibiotic activity of their own, they prevent bacterial degradation of beta-lactam antibiotics and thus extend the range of bacteria the drugs are effective against.

Pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae.

Pathogenic <i>Escherichia coli</i> Strains of E. coli that can cause disease

Escherichia coli is a gram-negative, rod-shaped bacterium that is commonly found in the lower intestine of warm-blooded organisms (endotherms). Most E. coli strains are harmless, but pathogenic varieties cause serious food poisoning, septic shock, meningitis, or urinary tract infections in humans. Unlike normal flora E. coli, the pathogenic varieties produce toxins and other virulence factors that enable them to reside in parts of the body normally not inhabited by E. coli, and to damage host cells. These pathogenic traits are encoded by virulence genes carried only by the pathogens.

Histophilus somni is a non-motile, gram-negative, rod or coccobacillus shaped, facultative anaerobe bacterial species belonging to the family Pasteurellaceae. Prior to 2003, it was thought Haemophilus somnus, Histophilus ovis, and Histophilus agni were three different species, but now are all classified as Histophilus somni. Histophilus somni is a commensal bacteria of mucous membranes of the upper respiratory tract and reproductive tract with a global prevalence and is found in cattle and other small ruminants. Histophilus somni is also a known causative agent that is a part of the Bovine Respiratory Disease (BRD) complex, which typically involves multiple pathogens residing together in biofilm environments. Histophilus somni may also cause Histophilosus symptoms and clinical presentation will depend on the tissue affected. When disease does occur, it can be difficult to catch in time and is often diagnosed post mortem. This means that treatment often involves metaphylactic mass treatment or no treatment at all. This organism is more fastidious than others and requires knowledge for sample collection, storage and culture. Genomic studies related to this bacteria have enabled scientists to pinpoint antibiotic resistance genes.  

Autogenous vaccines, also called autologous vaccines, autovaccines, “self” or custom vaccines, are vaccines that are prepared by isolation and destruction of microorganisms in infected individuals and used to provide immunity to the same individual.

References

  1. ↑ "Moraxella". List of Prokaryotic names with Standing in Nomenclature . Retrieved 2 May 2018.
  2. ↑ Embers ME, Doyle LA, Whitehouse CA, Selby EB, Chappell M, Philipp MT (January 2011). "Characterization of a Moraxella species that causes epistaxis in macaques". Veterinary Microbiology. 147 (3–4): 367–75. doi:10.1016/j.vetmic.2010.06.029. PMC   3971920 . PMID   20667430.
  3. ↑ Davidoss, N. H.; Varsak, Y. K.; Santa Maria, P. L. (1 June 2018). "Animal models of acute otitis media – A review with practical implications for laboratory research". European Annals of Otorhinolaryngology, Head and Neck Diseases. 135 (3): 183–190. doi:10.1016/j.anorl.2017.06.013. ISSN   1879-7296. PMID   29656888.
  4. 1 2 3 Verduin, Cees M.; Hol, Cees; Fleer, André; van Dijk, Hans; van Belkum, Alex (January 2002). "Moraxella catarrhalis : from Emerging to Established Pathogen". Clinical Microbiology Reviews. 15 (1): 125–144. doi:10.1128/CMR.15.1.125-144.2002. ISSN   0893-8512. PMC   118065 . PMID   11781271.
  5. ↑ Enright MC, McKenzie H (May 1997). "Moraxella (Branhamella) catarrhalis—clinical and molecular aspects of a rediscovered pathogen". Journal of Medical Microbiology. 46 (5): 360–71. doi: 10.1099/00222615-46-5-360 . PMID   9152030.
  6. ↑ "catarrhalis", Wiktionary, the free dictionary, 11 April 2021, retrieved 11 November 2024
  7. 1 2 Jakobsson HE, Salvà-Serra F, Thorell K, Gonzales-Siles L, Boulund F, Karlsson R, Sikora P, Engstrand L, Kristiansson E, Moore ER (June 2016). "Draft Genome Sequence of Moraxella catarrhalis Type Strain CCUG 353T". Genome Announcements. 4 (3): e00552–16. doi:10.1128/genomeA.00552-16. PMC   4911475 . PMID   27313296.
  8. ↑ "Moraxella catarrhalis strain CCUG 353, whole genome shotgun sequencing project". Infectious Diseases. 21 June 2016 – via GenBank.
  9. ↑ Mawas F, Ho MM, Corbel MJ (January 2009). "Current progress with Moraxella catarrhalis antigens as vaccine candidates". Expert Review of Vaccines. 8 (1): 77–90. doi:10.1586/14760584.8.1.77. PMID   19093775.
  10. ↑ Yu S, Gu XX (June 2007). "Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis". Infection and Immunity. 75 (6): 2974–80. doi:10.1128/IAI.01915-06. PMC   1932890 . PMID   17371852.
  11. 1 2 3 Murphy, Timothy F.; Parameswaran, G. Iyer (2009). "Moraxella catarrhalis, a Human Respiratory Tract Pathogen". Clinical Infectious Diseases. 49 (1): 124–131. doi:10.1086/599375. ISSN   1058-4838. JSTOR   40308788. PMID   19480579.
  12. 1 2 3 4 5 Winstanley TG, Spencer RC (September 1986). "Moraxella catarrhalis: antibiotic susceptibility with special reference to trimethoprim". The Journal of Antimicrobial Chemotherapy. 18 (3): 425–6. doi:10.1093/jac/18.3.425. PMID   3771428.
  13. 1 2 3 4 5 6 Helminen ME, Maciver I, Latimer JL, Klesney-Tait J, Cope LD, Paris M, McCracken GH, Hansen EJ (October 1994). "A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies". The Journal of Infectious Diseases. 170 (4): 867–72. doi:10.1093/infdis/170.4.867. PMID   7523537.
  14. 1 2 3 4 5 6 7 8 Melendez PR, Johnson RH (1991). "Bacteremia and septic arthritis caused by Moraxella catarrhalis". Reviews of Infectious Diseases. 13 (3): 428–9. doi:10.1093/clinids/13.3.428. PMID   1907759.
  15. 1 2 3 4 Maciver I, Unhanand M, McCracken GH, Hansen EJ (August 1993). "Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model". The Journal of Infectious Diseases. 168 (2): 469–72. doi:10.1093/infdis/168.2.469. PMID   8335988.
  16. 1 2 3 4 5 6 7 Ioannidis JP, Worthington M, Griffiths JK, Snydman DR (August 1995). "Spectrum and significance of bacteremia due to Moraxella catarrhalis". Clinical Infectious Diseases. 21 (2): 390–7. doi:10.1093/clinids/21.2.390. PMID   8562749.
  17. 1 2 Peng D, Hong W, Choudhury BP, Carlson RW, Gu XX (November 2005). "Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate". Infection and Immunity. 73 (11): 7569–77. doi:10.1128/IAI.73.11.7569-7577.2005. PMC   1273912 . PMID   16239560.
  18. ↑ Bootsma HJ, Aerts PC, Posthuma G, Harmsen T, Verhoef J, van Dijk H, Mooi FR (August 1999). "Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin?". Journal of Bacteriology. 181 (16): 5090–3. doi:10.1128/JB.181.16.5090-5093.1999. PMC   94001 . PMID   10438784.
  19. ↑ Schmitz, Franz-Josef; Beeck, Andreas; Perdikouli, Mirella; Boos, Mechthild; Mayer, Susanne; Scheuring, Sybille; Köhrer, Karl; Verhoef, Jan; Fluit, Ad C. (April 2002). "Production of BRO β-Lactamases and Resistance to Complement in European Moraxella catarrhalis Isolates". Journal of Clinical Microbiology. 40 (4): 1546–1548. doi:10.1128/jcm.40.4.1546-1548.2002. PMC   140350 . PMID   11923393.
  20. 1 2 3 4 5 Balder R, Shaffer TL, Lafontaine ER (June 2013). "Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2". BMC Microbiology. 13 (1): 140. doi: 10.1186/1471-2180-13-140 . PMC   3695778 . PMID   23782650.
  21. ↑ Schaar V, Nordström T, Mörgelin M, Riesbeck K (August 2011). "Moraxella catarrhalis outer membrane vesicles carry β-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin". Antimicrobial Agents and Chemotherapy. 55 (8): 3845–53. doi:10.1128/AAC.01772-10. PMC   3147650 . PMID   21576428.
  22. 1 2 3 Perez, Antonia C.; Murphy, Timothy F. (3 September 2019). "Potential impact of a Moraxella catarrhalis vaccine in COPD". Vaccine. 37 (37): 5551–5558. doi:10.1016/j.vaccine.2016.12.066. ISSN   0264-410X. PMC   5545157 . PMID   28185742.
  23. 1 2 3 4 Zahid, Ayesha; Wilson, Jennifer C.; Grice, I. Darren; Peak, Ian R. (24 January 2024). "Otitis media: recent advances in otitis media vaccine development and model systems". Frontiers in Microbiology. 15. doi: 10.3389/fmicb.2024.1345027 . ISSN   1664-302X. PMC   10847372 . PMID   38328427.
  24. ↑ Kano, Yasuhiro (1 April 2021). "Hockey puck sign: identifying Moraxella catarrhalis". BMJ Case Reports CP. 14 (4): e243677. doi:10.1136/bcr-2021-243677. ISSN   1757-790X. PMC   8189920 . PMID   33931430.
  25. ↑ Manual of Clinical Microbiology, 10th edition. James Versalovic, copyright 2012 ASM press.
  26. ↑ Palmer T, Berks BC (June 2012). "The twin-arginine translocation (Tat) protein export pathway". Nature Reviews. Microbiology. 10 (7): 483–96. doi:10.1038/nrmicro2814. PMID   22683878.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.